Advertisement

Pharmacy World and Science

, Volume 15, Supplement 1, pp 2–9 | Cite as

Drug transport across the blood-brain barrier

III. Mechanisms and methods to improve drug delivery to the central nervous system
  • J. B. M. M. Van Bree
  • A. G. De Boer
  • M. Danhof
  • D. D. Breimer
Reviews

Abstract

This is the third part of a review on the transport of drugs across the blood-brain barrier. In the first two parts, the anatomical and physiological aspects and the various techniques that can be used to study blood-brain transport have been discussed and reviewed. This third part focuses specifically on the mechanisms that are involved in drug transport across the blood-brain barrier. In addition, the opportunities to improve drug transport into the brain will be reviewed. Emphasis is on the transport of peptides.

Keywords

Biological transport Blood-brain barrier Cell membrane permeability Cerebrospinal fluid Peptides Prodrugs Proteins 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van Bree JBMM, De Boer, AG, Danhof M, Breimer DD. Drug transport across the blood-brain barrier. I. Anatomical and physiological aspects. Pharm Weekbl [Sci] 1992;14(5):305–10.Google Scholar
  2. 2.
    Van Bree JBMM, De Boer AG, Danhof M, Breimer DD. Drug transport across the blood-brain barrier. II. Experimental techniques to study drug transport. Pharm Weekbl [Sci] 1992;14(6):338–48.Google Scholar
  3. 3.
    Stein WD. The movement of molecules across cell membranes. New York: Academic Press, 1971:369.Google Scholar
  4. 4.
    Brodie BB, Kurz H, Shanker LS. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 1960;130:20–5.PubMedGoogle Scholar
  5. 5.
    Oldendorf WH. Lipid solubility and penetration of the blood-brain barrier. Proc Soc Exp Biol Med 1974;147:813–6.PubMedGoogle Scholar
  6. 6.
    Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res 1979;172:354–9.PubMedGoogle Scholar
  7. 7.
    Levin VA. Relationship of octanol/water partition coefficient and molecular weight of rat brain capillary permeability. J Med Chem 1980;23:682–4.PubMedGoogle Scholar
  8. 8.
    Oldendorf WH. Blood-brain barrier permeability to drugs. Ann Rev Pharmacol 1974;14:239–48.Google Scholar
  9. 9.
    Pardridge WM. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin bound hormone. Endocrinology 1979;105:605–12.PubMedGoogle Scholar
  10. 10.
    Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 1988;245:816–22.PubMedGoogle Scholar
  11. 11.
    Pardridge WM, Landaw EM. Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. J Clin Invest 1974;74:745–52.Google Scholar
  12. 12.
    Pardridge WM. Plasma protein-mediated transport of steroid and thyroid hormones. Am J Physiol 1987;252:E157–64.PubMedGoogle Scholar
  13. 13.
    Forker EL, Luxon BA. Albumin-mediated transport of rose bengal: kinetics of reactions at the cell surface. J Clin Invest 1983;72:1764–71.PubMedGoogle Scholar
  14. 14.
    Rehfeld JF. Localisation of gastrins to neuro- and adenohypophysis. Nature 1978;271:771–3.PubMedGoogle Scholar
  15. 15.
    Muller JE, Sraus E, Yalow RS. Cholecystokinin and its COOH-terminal octapeptide in pig brain. Proc Natl Acad Sci USA 1977;74:3035–7.PubMedGoogle Scholar
  16. 16.
    Giachetti A, Said SI, Reynolds RC, Koniges FC. Vasoactive intestinal polypeptide in brain: localisation in and release from isolated nerve terminals. Proc Natl Acad Sci USA 1977;74:3424–8.PubMedGoogle Scholar
  17. 17.
    Mutt V, Carlquist M, Tatemoto K. Secretin-like bioactivity in extracts of porcine brain. Life Sci 1979;25:1703–8.PubMedGoogle Scholar
  18. 18.
    Havrankova J, Schmechel D, Brownstein M. Identification of insulin in rat brain. Proc Natl Acad Sci USA 1978;75:5737–41.PubMedGoogle Scholar
  19. 19.
    Greven HM, De Wied D. Neuropeptides and behaviour. In: Eberle A, Geiger R, Wieland T, eds. Perspectives in peptide chemistry. Basel: Karger, 1981:358–71.Google Scholar
  20. 20.
    Kovacs GL, Veldhuis HD, Versteeg DHG, De Wied D. Facilitation of avoidance behaviour by vasopressin fragments microinjected into limbic-midbrain structures. Brain Res 1986;371:17–24.PubMedGoogle Scholar
  21. 21.
    Meisenberg, G, Simmons WH. Centrally mediated effects of neurohypophyseal hormones. Neurosci Behav Rev 1983;7:263–80.Google Scholar
  22. 22.
    Cornford EM, Braun LD, Crane PD, Oldendorf WH. Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 1978;103:1297–303.PubMedGoogle Scholar
  23. 23.
    Houghten RA, Swann RW, Li CH.β-Endorphin: stability, clearance behaviour and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits. Proc Natl Acad Sci USA 1980;77:4588–91.PubMedGoogle Scholar
  24. 24.
    Ang VTY, Jenkins JS. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog. J Endocrinol 1982;93:319–25.PubMedGoogle Scholar
  25. 25.
    Zhu XG, Greeley GH, Lewis BG, Lilja P, Thompson JC. Blood-cerebrospinal fluid barrier to CCK and effect of centrally administered bombesin on release of brain CCK. J Neurosci Res 1986;15:393–403.PubMedGoogle Scholar
  26. 26.
    Levin ER, Frank HJL, Weber MA, Ismail M, Mills S. Studies on the penetration of the blood-brain barrier by atrial natriuretic factor. Biochem Biophys Res Commun 1987;147:1226–31.PubMedGoogle Scholar
  27. 27.
    Hersh, LB, McKelvy JF. An aminopeptidase from bovine brain which catalyses the hydrolysis of enkephalin. J Neurochem 1981;36:171–8.PubMedGoogle Scholar
  28. 28.
    Verhoef JC, Scholtens H, Vergeer EG, Witter A. Des-tyrgamma-endorphin (DyγE) and des-enkephalin-gamma-endorphin (DEγE): plasma profile and brain uptake after systemic administration in the rat. Peptides 1985;6:467–74.PubMedGoogle Scholar
  29. 29.
    Riekkinnen P, Legros JJ, Sennef C, Jolkkonen J, Smitz S, Soininen H. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects. Peptides 1987; 8:261–5.PubMedGoogle Scholar
  30. 30.
    Collins JM, Dedrick RL. Distributed model for drug delivery to cerebrospinal fluid and brain tissue. Am J Physiol 1983;245:R303–10.PubMedGoogle Scholar
  31. 31.
    Grundy HF. Circulation of cerebrospinal fluid in the spinal region of the cat. J Physiol 1962;163:457–65.PubMedGoogle Scholar
  32. 32.
    Rall DP, Oppelt WW, Patlak CS. Extracellular space of brain as determined by infusion of inulin from the ventricular system. Life Sci 1962;2:43–8.Google Scholar
  33. 33.
    Kastin AJ, Nissen Ch, Coy DH. Permeability of blood-brain barrier to DSIP peptides. Pharmacol Biochem Behav 1981;15:955–9.PubMedGoogle Scholar
  34. 34.
    Greig NH, Soncrant TT, Wozniak KM, Rapoport SI. Plasma and tissue pharmacokinetics of human interferon-α in the rat after its intravenous administration. J Pharmacol Exp Ther 1988;245:574–80.PubMedGoogle Scholar
  35. 35.
    Van Bree JBMM, Tio S, De Boer AG, Danhof M, Verhoef JC, Breimer DD. Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. Pharm Res 1990;7(3):292–307.Google Scholar
  36. 36.
    Banks WA, Kastin AJ. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 1985;15:287–92.PubMedGoogle Scholar
  37. 37.
    Van Bree JBMM, De Boer AG, Danhof M, Ginsel LA, Breimer DD. Characterization of anin vitro blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 1988;247(3):1233–9.PubMedGoogle Scholar
  38. 38.
    Van Bree JBMM, De Boer AG, Verhoef JC, Danhof M, Breimer DD. Transport of vasopressin fragments across the blood-brain barrier:in vitro studies using monolayer cultures of bovine brain endothelial cells. J Pharmacol Exp Ther 1989;249:901–5.PubMedGoogle Scholar
  39. 39.
    Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987;18:299–304.PubMedGoogle Scholar
  40. 40.
    Frank HJL, Pardridge WM, Morris WL, Rosenfeld RG, Choi TB. Binding and internalisation of insulin and insulin-like growth factor by isolated brain microvessels. Diabetes 1986; 35:654–61.PubMedGoogle Scholar
  41. 41.
    Banks WA, Kastin AJ. A brain to blood carrier-mediated transport system for small,N-tyrosinated peptides. Pharmacol Biochem Behav 1984;21:943–6.PubMedGoogle Scholar
  42. 42.
    Banks WA, Kastin AJ, Horvath A, Michals EA. Carrier-mediated transport of vasopressin across the blood-brain barrier of the mouse. J Neurosci Res 1987;18:326–32.PubMedGoogle Scholar
  43. 43.
    Banks WA, Kastin AJ. Inhibition of the brain to blood transport system for enkephalins and Tyr-MIF-1 in mice addicted or genetically predisposed to drinking ethanol. Alcohol 1989;6:53–7.PubMedGoogle Scholar
  44. 44.
    Zlokovic BV, Segal MB, Begley DJ. Permeability of the isolated choroid plexus of the sheep to thyrotropin releasing hormone. In: Yudelevich DL, Mann GE, eds. Carriermediated transport of solutes from brain to tissue. London: Longmans, 1985:307–12.Google Scholar
  45. 45.
    Ommaya A. A subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet 1963;2:983–4.Google Scholar
  46. 46.
    Barranger JA, Rapoport SI, Fredericks WR, Pentchev PG, MacDermot KD, Steusing JK, et al. Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc Natl Acad Sci 1979;76:481–5.PubMedGoogle Scholar
  47. 47.
    Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 1980;238:R421–31.PubMedGoogle Scholar
  48. 48.
    Neuwelt EA, Barnett PA, Hellstrom KE, Beaumier P, McCormick CI, Weigel RM. Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988;48:4725–9.PubMedGoogle Scholar
  49. 49.
    Neuwelt EA, Rapoport SI. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc 1984;43:214–9.PubMedGoogle Scholar
  50. 50.
    Hiesmayr M, Dirnberger H, Aloy A, Heimberger K, Horaczek A, Brandstatter B, et al. Haemodynamic effects of a osmotic bolus for the reversible opening of the blood-brain barrier. Schweiz Med Wochenschr 1987;117:450–4.PubMedGoogle Scholar
  51. 51.
    Warnke PC, Blasberg RG, Groothuis DR. The effect of hyperosmotic blood-brain barrier disruption on blood to tissue transport in ENU-induced gliomas. Ann Neurol 1987;22:300–5.PubMedGoogle Scholar
  52. 52.
    Suzuki M, Iwasaki Y, Yamamoto T, Konno H, Kudo H. Sequelae of osmotic blood-brain barrier opening in rats. J Neurosurg 1988;69:421–8.PubMedGoogle Scholar
  53. 53.
    Gross PM, Teasdale GM, Graham DI, Angerson WJ, Harper AM. Intra-arterial histamine increases blood-brain transport in rats. Am J Physiol 1092;243:H307–17.Google Scholar
  54. 54.
    Domer FR, Boertje SB, Bing EG, Reddin I. Histamine and acetylcholine-induced changes in the permeability of the blood-brain barrier of normotensive and spontaneously hypertensive rats. Neuropharmacology 1983;22:615–9.PubMedGoogle Scholar
  55. 55.
    Banks WA, Kastin AJ. Aluminium increases permeability of the blood-brain barrier to labelled DSIP andβ-endorphin: possible implications for senile and dialysis dementia. Lancet 1983;1:1227–9.Google Scholar
  56. 56.
    Raymond, JJ, Robertson DM, Dinsdale HB, Nag S. Pharmacological modification of blood-brain barrier permeability following a cold lesion. Can J Neurol Sci 1984;11:447–51.PubMedGoogle Scholar
  57. 57.
    Gulati A, Nath C, Shanker K, Srimal RC. Effect of alcohols on the permeability of blood-brain barrier. Pharmacol Res Commun 1985;17:85–93.PubMedGoogle Scholar
  58. 58.
    Nishihata T, Cho R, Kato J, Kamada A. Effect of salicylate on the uptake of cefmetazole into mice brain. Pharm Res 1985;5:243–5.Google Scholar
  59. 59.
    Zapulla RA, Spigelman MK, Omsberg E, Rosen JJ, Malis LI, Holland JF. EEG consequences of sodium dehydrocholate-induced blood-brain barrier disruption. Part 1. Neurosurgery 1985;16:630–8.PubMedGoogle Scholar
  60. 60.
    Spigelman MK, Zappulla RA, Strauchen JA, Feuer EJ, Johnson J, Goldsmith SJ, et al. Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae. Cancer Res 1986;46:1453–7.PubMedGoogle Scholar
  61. 61.
    Raymond JJ, Robertson DM, Dinsdale HB. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 1986;13:214–20.PubMedGoogle Scholar
  62. 62.
    Strausbaugh LJ. Intracarotid infusions of protamine sulfate disrupt the blood-brain barrier of rabbits. Brain Res 1987; 409:221–6.PubMedGoogle Scholar
  63. 63.
    Sharma HS. Effect of captopril on blood-brain barrier permeability and cerebral blood flow in normotensive rats. Neuropharmacology 1987;26:85–92.PubMedGoogle Scholar
  64. 64.
    Sokrab TEO, Johansson BB, Kalimo H, Olsson Y. A transient hypertensive opening of the blood-brain barrier can lead to brain damage. Acta Neuropathol 1988;75:557–65.PubMedGoogle Scholar
  65. 65.
    Baba M, Oishi R, Saeki K. Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation ofμ opioid receptors in mice. Arch Pharmacol 1988;337:423–8.Google Scholar
  66. 66.
    Greig NH. Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA, ed. Implications of the blood-brain barrier and its manipulation. New York: Plenum, 1989:311–67. (Basic science aspects; vol. 1.)Google Scholar
  67. 67.
    Bodor N, Shek E, Higuchi T. Delivery of a quaternary pyridinium salt across the blood-brain barrier as its dihydropyridine derivative. Science 1975;190:155–6.PubMedGoogle Scholar
  68. 68.
    Nutt JG, Woodward WR, Hammerstad JP. The on-off phenomenon in Parkinson's disease: relation to levodopa and transport. N Engl J Med 1984;310:483–8.PubMedGoogle Scholar
  69. 69.
    Partridge WM. Peptide drug delivery to the brain. New York: Raven Press, 1991.Google Scholar

Copyright information

© Periodicals Service Company 1993

Authors and Affiliations

  • J. B. M. M. Van Bree
    • 1
  • A. G. De Boer
    • 1
  • M. Danhof
    • 1
  • D. D. Breimer
    • 1
  1. 1.Leiden/Amsterdam Center for Drug Research, Division of PharmacologyLeiden UniversityRA Leidenthe Netherlands

Personalised recommendations